Interplay between hypoxia and inflammation in cancer progression, therapy resistance, and natural cancer resistance

Yandong Xu; Yang Zhao

doi:10.70401/acrt.2026.0032

Interplay between hypoxia and inflammation in cancer progression, therapy resistance, and natural cancer resistance

Yandong Xu

1,2

Yang Zhao

1,2,*

Affiliation +

*Correspondence to: Yang Zhao, Department of Physiology and Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 301158, Zhejiang, China. E-mail: yang.zhao@zju.edu.cn

Ageing Cancer Res Treat. 2026;3:202612. 10.70401/acrt.2026.0032

Received: March 23, 2026Accepted: July 17, 2026Published: July 17, 2026

This manuscript is made available in its unedited form to allow early access to the reported findings. Further editing will be completed before final publication. As such, the content may include errors, and standard legal disclaimers are applicable.

Abstract

The microenvironment of solid tumors is characterized by dynamic availability of oxygen and persistent, complex inflammatory signaling. Accumulating evidence suggests that hypoxia and inflammation actively influence tumor progression and therapeutic response. In physiological conditions, hypoxic and inflammatory responses function as evolutionarily conserved protective mechanisms. Acute hypoxia promotes temporary metabolic adaptation to preserve tissue viability, while acute inflammation facilitates clearance of damaged or abnormal cells and restores homeostasis. In tumors, by contrast, hypoxia and inflammation become chronic and unresolved. Persistent activation of these protective signals gradually renders the microenvironment permissive to the sustained adaptation of abnormal cells rather than eliminating them. This transition from clearance to tolerance reshapes cellular metabolism, immune cell behavior, and tissue organization within the tumor microenvironment. As a result, tumor cells increasingly adapt to metabolic stress and evade effective immune surveillance, contributing to malignancy and therapy resistance. Interestingly, some subterranean species, including the naked mole rat and blind mole rat, show natural cancer resistance. They either evolved adaptations counteracting inflammation, or take the immune response to their advantage to prevent cancer. These anti-cancer mechanisms are a result of adaptation to their hypoxic subterranean habitats. In this review, we examine the fundamental features of hypoxia and inflammation in tumors, explore their functional interplay, and discuss how these mechanisms are evaded or harnessed by cancer resistant subterranean mammals. We further propose a simple clearance to resistance framework that links acute protective stress responses, chronic tumor-promoting adaptation, and naturally evolved cancer resistance.

Keywords

Cancer resistance, hypoxia, inflammation, subterranean species

References

1. Dey P, Kimmelman AC, DePinho RA. Metabolic codependencies in the tumor microenvironment. Cancer Discov. 2021;11(5):1067-1081.

[DOI] [PubMed] [PMC]
2. Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23(1):27-47.

[DOI]
3. Kumar KH, Venakteshaiah SU. Inflammation and cancer. Endocr Metab Immune Disord Drug Targets. 2021;21(2):193-194.

[DOI]
4. DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, et al. CD4⁺ T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell. 2009;16(2):91-102.

[DOI] [PubMed] [PMC]
5. Condeelis J, Pollard JW. Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006;124(2):263-266.

[DOI] [PubMed]
6. Gallimore AM, Simon AK. Positive and negative influences of regulatory T cells on tumour immunity. Oncogene. 2008;27(45):5886-5893.

[DOI]
7. Pham K, Parikh K, Heinrich EC. Hypoxia and inflammation: Insights from high-altitude physiology. Front Physiol. 2021;12:676782.

[DOI]
8. Buffenstein R, Jarvis JU. The naked mole rat: A new record for the oldest living rodent. Sci Aging Knowledge Environ. 2002;2002(21):pe7.

[DOI] [PubMed]
9. Zhao Y, Seluanov A, Gorbunova V. Revelations about aging and disease from unconventional vertebrate model organisms. Annu Rev Genet. 2021;55:135-159.

[DOI] [PubMed] [PMC]
10. Bosco MC, D’Orazi G, Del Bufalo D. Targeting hypoxia in tumor: A new promising therapeutic strategy. J Exp Clin Cancer Res. 2020;39(1):8.

[DOI]
11. Varsha VK, Savita JK, Girish HC, Shyamala K. Role of hypoxia and epithelial-mesenchymal transition in the formation and maintenance of oral cancer stem cells in oral squamous cell carcinomas and metastatic lymph node: An immunohistochemical analysis. J Oral Maxillofac Pathol. 2023;27(2):307-314.

[DOI] [PubMed] [PMC]
12. Stuart AJ, Takai KK, Gabbasova RR, Sanford H, Vinogradova EV, de Lange T, et al. Attenuation of ATM signaling by ROS delays replicative senescence at physiological oxygen. Mol Cell. 2025;85(24):4667-4677.e7.

[DOI] [PubMed] [PMC]
13. Taylor CT, Scholz CC. The effect of HIF on metabolism and immunity. Nat Rev Nephrol. 2022;18(9):573-587.

[DOI]
14. Volkova YL, Pickel C, Jucht AE, Wenger RH, Scholz CC. The asparagine hydroxylase FIH: A unique oxygen sensor. Antioxid Redox Signal. 2022;37(13-15):913-935.

[DOI] [PubMed]
15. Batie M, Frost J, Frost M, Wilson JW, Schofield P, Rocha S, et al. Hypoxia induces rapid changes to histone methylation and reprograms chromatin. Science. 2019;363(6432):1222-1226.

[DOI] [PubMed]
16. Myllyharju J, Kivirikko KI. Collagens, modifying enzymes and their mutations in humans, flies and worms. Trends Genet. 2004;20(1):33-43.

[DOI] [PubMed]
17. Hosseini A, Dhall A, Ikonen N, Sikora N, Nguyen S, Shen Y, et al. Perturbing LSD1 and WNT rewires transcription to synergistically induce AML differentiation. Nature. 2025;642(8067):508-518.

[DOI] [PubMed] [PMC]
18. Melvin A, Rocha S. Chromatin as an oxygen sensor and active player in the hypoxia response. Cell Signal. 2012;24(1):35-43.

[DOI]
19. Williams ST, Walport LJ, Hopkinson RJ, Madden SK, Chowdhury R, Schofield CJ, et al. Studies on the catalytic domains of multiple JmjC oxygenases using peptide substrates. Epigenetics. 2014;9(12):1596-1603.

[DOI] [PubMed] [PMC]
20. Shmakova A, Batie M, Druker J, Rocha S. Chromatin and oxygen sensing in the context of JmjC histone demethylases. Biochem J. 2014;462(3):385-395.

[DOI] [PubMed] [PMC]
21. Smolle M, Workman JL. Transcription-associated histone modifications and cryptic transcription. Biochim Biophys Acta. 2013;1829(1):84-97.

[DOI] [PubMed] [PMC]
22. Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004;119(7):941-953.

[DOI] [PubMed]
23. Chakraborty AA, Laukka T, Myllykoski M, Ringel AE, Booker MA, Tolstorukov MY, et al. Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate. Science. 2019;363(6432):1217-1222.

[DOI] [PubMed] [PMC]
24. McDonough MA, Loenarz C, Chowdhury R, Clifton IJ, Schofield CJ. Structural studies on human 2-oxoglutarate dependent oxygenases. Curr Opin Struct Biol. 2010;20(6):659-672.

[DOI]
25. Rose NR, McDonough MA, King ONF, Kawamura A, Schofield CJ. Inhibition of 2-oxoglutarate dependent oxygenases. Chem Soc Rev. 2011;40(8):4364.

[DOI]
26. Guido C, Whitaker-Menezes D, Capparelli C, Balliet R, Lin Z, Pestell RG, et al. Metabolic reprogramming of cancer-associated fibroblasts by TGF-β drives tumor growth: Connecting TGF-β signaling with “Warburg-like” cancer metabolism and L-lactate production. Cell Cycle. 2012;11(16):3019-3035.

[DOI] [PubMed] [PMC]
27. Martí-Mateos Y, Safari Z, Bevers S, Midha AD, Flanigan WR, Joshi T, et al. Red blood cells serve as a primary glucose sink to improve glucose tolerance at altitude. Cell Metab. 2026;38(3):529-545.e8.

[DOI] [PubMed] [PMC]
28. Koppenol WH, Bounds PL, Dang CV. Otto Warburg’s contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011;11(5):325-337.

[DOI] [PubMed]
29. Wu Q, You L, Nepovimova E, Heger Z, Wu W, Kuca K, et al. Hypoxia-inducible factors: Master regulators of hypoxic tumor immune escape. J Hematol Oncol. 2022;15(1):77.

[DOI]
30. Bose S, Panda AK, Mukherjee S, Sa G. Curcumin and tumor immune-editing: Resurrecting the immune system. Cell Div. 2015;10:6.

[DOI] [PubMed] [PMC]
31. Liikanen I, Lauhan C, Quon S, Omilusik K, Phan AT, Bartrolí LB, et al. Hypoxia-inducible factor activity promotes antitumor effector function and tissue residency by CD8⁺ T cells. J Clin Invest. 2021;131(7):e143729.

[DOI] [PubMed] [PMC]
32. He Y, Korboukh I, Jin J, Huang J. Targeting protein lysine methylation and demethylation in cancers. Acta Biochim Biophys Sin. 2012;44(1):70-79.

[DOI]
33. Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18(1):10.

[DOI] [PubMed] [PMC]
34. Martinez-Bosch N, Vinaixa J, Navarro P. Immune evasion in pancreatic cancer: From mechanisms to therapy. Cancers. 2018;10(1):6.

[DOI]
35. Barsoum IB, Smallwood CA, Siemens DR, Graham CH. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res. 2014;74(3):665-674.

[DOI] [PubMed]
36. Ortega-Sáenz P, López-Barneo J. Physiology of the carotid body: From molecules to disease. Annu Rev Physiol. 2020;82:127-149.

[DOI]
37. Cummins EP, Strowitzki MJ, Taylor CT. Mechanisms and consequences of oxygen and carbon dioxide sensing in mammals. Physiol Rev. 2020;100(1):463-488.

[DOI]
38. Bae T, Hallis SP, Kwak MK. Hypoxia, oxidative stress, and the interplay of HIFs and NRF2 signaling in cancer. Exp Mol Med. 2024;56(3):501-514.

[DOI]
39. Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008;454(7203):428-435.

[DOI]
40. Barton GM. A calculated response: Control of inflammation by the innate immune system. J Clin Invest. 2008;118(2):413-420.

[DOI]
41. Medzhitov R. Inflammation 2010: New adventures of an old flame. Cell. 2010;140(6):771-776.

[DOI] [PubMed]
42. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991-998.

[DOI]
43. Dou Z, Ghosh K, Vizioli MG, Zhu J, Sen P, Wangensteen KJ, et al. Cytoplasmic chromatin triggers inflammation in senescence and cancer. Nature. 2017;550(7676):402-406.

[DOI]
44. Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell. 2015;162(5):974-986.

[DOI] [PubMed] [PMC]
45. Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY, et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell. 2015;162(5):961-973.

[DOI] [PubMed] [PMC]
46. Sheng W, LaFleur MW, Nguyen TH, Chen S, Chakravarthy A, Conway JR, et al. LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade. Cell. 2018;174(3):549-563.e19.

[DOI] [PubMed] [PMC]
47. Zhao Y, Simon M, Seluanov A, Gorbunova V. DNA damage and repair in age-related inflammation. Nat Rev Immunol. 2023;23(2):75-89.

[DOI]
48. Fernandes Q, Inchakalody VP, Bedhiafi T, Mestiri S, Taib N, Uddin S, et al. Chronic inflammation and cancer; the two sides of a coin. Life Sci. 2024;338:122390.

[DOI]
49. Cheon H, Wang Y, Wightman SM, Jackson MW, Stark GR. How cancer cells make and respond to interferon-I. Trends Cancer. 2023;9(1):83-92.

[DOI]
50. Ramsdell F, Lantz T, Fowlkes BJ. A nondeletional mechanism of thymic self tolerance. Science. 1989;246(4933):1038-1041.

[DOI]
51. Kenison JE, Stevens NA, Quintana FJ. Therapeutic induction of antigen-specific immune tolerance. Nat Rev Immunol. 2024;24(5):338-357.

[DOI]
52. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: The central role of the HIF hydroxylase pathway. Mol Cell. 2008;30(4):393-402.

[DOI] [PubMed]
53. Perkins ND. Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway. Oncogene. 2006;25(51):6717-6730.

[DOI]
54. Figueroa YG, Chan AK, Ibrahim R, Tang Y, Burow ME, Alam J, et al. NF-κB plays a key role in hypoxia-inducible factor-1-regulated erythropoietin gene expression. Exp Hematol. 2002;30(12):1419-1427.

[DOI]
55. Taylor CT. Interdependent roles for hypoxia inducible factor and nuclear factor-kappaB in hypoxic inflammation. J Physiol. 2008;586(17):4055-4059.

[DOI] [PubMed] [PMC]
56. Belaiba RS, Bonello S, Zähringer C, Schmidt S, Hess J, Kietzmann T, et al. Hypoxia up-regulates hypoxia-inducible factor-1alpha transcription by involving phosphatidylinositol 3-kinase and nuclear factor kappaB in pulmonary artery smooth muscle cells. Mol Biol Cell. 2007;18(12):4691-4697.

[DOI] [PubMed] [PMC]
57. Frede S, Stockmann C, Freitag P, Fandrey J. Bacterial lipopolysaccharide induces HIF-1 activation in human monocytes via p44/42 MAPK and NF-κB. Biochem J. 2006;396(3):517-527.

[DOI]
58. Du F, Yu Q, Hu G, Lin CS, ShiDu Yan S. PINK1-dependent NFKB signaling contributes to amyloid pathology in Alzheimer disease. Autophagy. 2025;21(12):2561-2577.

[DOI] [PubMed] [PMC]
59. Alicea Pauneto CDM, Riesenberg BP, Gandy EJ, Kennedy AS, Clutton GT, Hem JW, et al. Intra-tumoral hypoxia promotes CD8⁺ T cell dysfunction via chronic activation of integrated stress response transcription factor ATF4. Immunity. 2025;58(10):2489-2504.e8.

[DOI] [PubMed] [PMC]
60. Sattiraju A, Kang S, Giotti B, Chen Z, Marallano VJ, Brusco C, et al. Hypoxic niches attract and sequester tumor-associated macrophages and cytotoxic T cells and reprogram them for immunosuppression. Immunity. 2023;56(8):1825-1843.e6.

[DOI] [PubMed] [PMC]
61. Miar A, Arnaiz E, Bridges E, Beedie S, Cribbs AP, Downes DJ, et al. Hypoxia induces transcriptional and translational downregulation of the type I IFN pathway in multiple cancer cell types. Cancer Res. 2020;80(23):5245-5256.

[DOI] [PubMed] [PMC]
62. Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, et al. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014;211(5):781-790.

[DOI]
63. Zhang H, Lu H, Xiang L, Bullen JW, Zhang C, Samanta D, et al. HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells. Proc Natl Acad Sci U S A. 2015;112(45):E6215-E6223.

[DOI]
64. Robles-Oteíza C, Hastings K, Choi J, Sirois I, Ravi A, Expósito F, et al. Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer. J Exp Med. 2025;222(1):e20231106.

[DOI] [PubMed] [PMC]
65. Choueiri TK, Powles T, Peltola K, de Velasco G, Burotto M, Suarez C, et al. Belzutifan versus everolimus for advanced renal-cell carcinoma. N Engl J Med. 2024;391(8):710-721.

[DOI]
66. Zhao J, Tian X, Zhu Y, Zhang Z, Rydkina E, Yuan Y, et al. Reply to: Transformation of naked mole-rat cells. Nature. 2020;583(7814):E8-E13.

[DOI]
67. Chen Y, Chen Z, Wang H, Cui Z, Li KL, Song Z, et al. A cGAS-mediated mechanism in naked mole-rats potentiates DNA repair and delays aging. Science. 2025;390(6769):eadp5056.

[DOI] [PubMed]
68. Land H, Parada LF, Weinberg RA. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature. 1983;304(5927):596-602.

[DOI] [PubMed]
69. Miyawaki S, Kawamura Y, Oiwa Y, Shimizu A, Hachiya T, Bono H, et al. Tumour resistance in induced pluripotent stem cells derived from naked mole-rats. Nat Commun. 2016;7:11471.

[DOI] [PubMed] [PMC]
70. Tan L, Ke Z, Tombline G, Macoretta N, Hayes K, Tian X, et al. Naked mole rat cells have a stable epigenome that resists iPSC reprogramming. Stem Cell Reports. 2017;9(5):1721-1734.

[DOI] [PubMed] [PMC]
71. Tian X, Azpurua J, Hine C, Vaidya A, Myakishev-Rempel M, Ablaeva J, et al. High-molecular-mass hyaluronan mediates the cancer resistance of the naked mole rat. Nature. 2013;499(7458):346-349.

[DOI] [PubMed] [PMC]
72. Tian X, Azpurua J, Ke Z, Augereau A, Zhang ZD, Vijg J, et al. INK4locus of the tumor-resistant rodent, the naked mole rat, expresses a functional p15/p16 hybrid isoform. Proc Natl Acad Sci U S A. 2015;112(4):1053-1058.

[DOI]
73. Boila LD, Ghosh S, Bandyopadhyay SK, Jin L, Murison A, Zeng AGX, et al. KDM6 demethylases integrate DNA repair gene regulation and loss of KDM6A sensitizes human acute myeloid leukemia to PARP and BCL2 inhibition. Leukemia. 2023;37(4):751-764.

[DOI] [PubMed] [PMC]
74. Kothapalli D, Zhao L, Hawthorne EA, Cheng Y, Lee E, Puré E, et al. Hyaluronan and CD44 antagonize mitogen-dependent cyclin D1 expression in mesenchymal cells. J Cell Biol. 2007;176(4):535-544.

[DOI] [PubMed] [PMC]
75. Toole BP. Hyaluronan: From extracellular glue to pericellular cue. Nat Rev Cancer. 2004;4(7):528-539.

[DOI] [PubMed]
76. Taylor KR, Milone NA, Rodriguez CE. Four cases of spontaneous neoplasia in the naked mole-rat (Heterocephalus glaber), a putative cancer-resistant species. J Gerontol A Biol Sci Med Sci. 2017;72(1):38-43.

[DOI]
77. Takasugi M, Firsanov D, Tombline G, Ning H, Ablaeva J, Seluanov A, et al. Naked mole-rat very-high-molecular-mass hyaluronan exhibits superior cytoprotective properties. Nat Commun. 2020;11(1):2376.

[DOI] [PubMed] [PMC]
78. Zhang Z, Tian X, Lu JY, Boit K, Ablaeva J, Zakusilo FT, et al. Increased hyaluronan by naked mole-rat Has2 improves healthspan in mice. Nature. 2023;621(7977):196-205.

[DOI] [PubMed] [PMC]
79. Zhao Y, Zheng Z, Zhang Z, Xu Y, Hillpot E, Lin YS, et al. Evolution of high-molecular-mass hyaluronic acid is associated with subterranean lifestyle. Nat Commun. 2023;14(1):8054.

[DOI] [PubMed] [PMC]
80. Gorbunova V, Hine C, Tian X, Ablaeva J, Gudkov AV, Nevo E, et al. Cancer resistance in the blind mole rat is mediated by concerted necrotic cell death mechanism. Proc Natl Acad Sci U S A. 2012;109(47):19392-19396.

[DOI]
81. Fang X, Nevo E, Han L, Levanon EY, Zhao J, Avivi A, et al. Genome-wide adaptive complexes to underground stresses in blind mole rats Spalax. Nat Commun. 2014;5:3966.

[DOI] [PubMed]
82. Zhao Y, Oreskovic E, Zhang Q, Lu Q, Gilman A, Lin YS, et al. Transposon-triggered innate immune response confers cancer resistance to the blind mole rat. Nat Immunol. 2021;22(10):1219-1230.

[DOI]
83. Ashur-Fabian O, Avivi A, Trakhtenbrot L, Adamsky K, Cohen M, Kajakaro G, et al. Evolution of p53 in hypoxia-stressed Spalax mimics human tumor mutation. Proc Natl Acad Sci U S A. 2004;101(33):12236-12241.

[DOI]
84. Leonova KI, Brodsky L, Lipchick B, Pal M, Novototskaya L, Chenchik AA, et al. p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs. Proc Natl Acad Sci U S A. 2013;110(1):E89-E98.

[DOI]
85. Tyshkovskiy A, Ma S, Shindyapina AV, Tikhonov S, Lee SG, Bozaykut P, et al. Distinct longevity mechanisms across and within species and their association with aging. Cell. 2023;186(13):2929-2949.e20.

[DOI]
86. Swovick K, Firsanov D, Welle KA, Hryhorenko JR, Wise JP Sr, George C, et al. Interspecies differences in proteome turnover kinetics are correlated with life spans and energetic demands. Mol Cell Proteomics. 2021;20:100041.

[DOI] [PubMed] [PMC]
87. Seim I, Ma S, Zhou X, Gerashchenko MV, Lee SG, Suydam R, et al. The transcriptome of the bowhead whale Balaena mysticetus reveals adaptations of the longest-lived mammal. Aging. 2014;6(10):879-899.

[DOI] [PubMed] [PMC]
88. Jensen FB. The role of nitrite in nitric oxide homeostasis: A comparative perspective. Biochim Biophys Acta. 2009;1787(7):841-848.

[DOI] [PubMed]
89. Firsanov D, Zacher M, Tian X, Sformo TL, Zhao Y, Tombline G, et al. Evidence for improved DNA repair in the long-lived bowhead whale. Nature. 2025;648(8094):717-725.

[DOI] [PubMed] [PMC]

Copyright

© The Author(s) 2026. This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Publisher’s Note

Science Exploration remains a neutral stance on jurisdictional claims in published maps and institutional affiliations. The views expressed in this article are solely those of the author(s) and do not reflect the opinions of the Editors or the publisher.

Share And Cite

Science Exploration Style

Xu Y, Zhao Y. Interplay between hypoxia and inflammation in cancer progression, therapy resistance, and natural cancer resistance. Ageing Cancer Res Treat. 2026;3:202612. https://doi.org/10.70401/acrt.2026.0032